177 related articles for article (PubMed ID: 26826279)
21. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis.
Guggenberg EV; Mikolajczak R; Janota B; Riccabona G; Decristoforo C
J Pharm Sci; 2004 Oct; 93(10):2497-506. PubMed ID: 15349959
[TBL] [Abstract][Full Text] [Related]
22. Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptor.
Kolenc Peitl P; Tamma M; Kroselj M; Braun F; Waser B; Reubi JC; Sollner Dolenc M; Maecke HR; Mansi R
Bioconjug Chem; 2015 Jun; 26(6):1113-9. PubMed ID: 25971921
[TBL] [Abstract][Full Text] [Related]
23. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
24. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
25. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma.
Fröberg AC; de Jong M; Nock BA; Breeman WA; Erion JL; Maina T; Verdijsseldonck M; de Herder WW; van der Lugt A; Kooij PP; Krenning EP
Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1265-72. PubMed ID: 19266197
[TBL] [Abstract][Full Text] [Related]
26. Lyophilization of NOTA-sdAbs: First step towards a cold diagnostic kit for
Baudhuin H; Van Bockstal PJ; De Beer T; Vaneycken I; Bridoux J; Raes G; Caveliers V; Keyaerts M; Devoogdt N; Lahoutte T; Xavier C
Eur J Pharm Biopharm; 2021 Sep; 166():194-204. PubMed ID: 34186190
[TBL] [Abstract][Full Text] [Related]
27. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
28. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
29. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
[TBL] [Abstract][Full Text] [Related]
30. Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions.
Klingler M; Hörmann AA; Guggenberg EV
Curr Med Chem; 2020; 27(41):7112-7132. PubMed ID: 32586246
[TBL] [Abstract][Full Text] [Related]
31. Standardization of Procedures for the Preparation of (177)Lu- and (90)Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation.
Wojdowska W; Karczmarczyk U; Maurin M; Garnuszek P; Mikołajczak R
Curr Radiopharm; 2015; 8(1):62-8. PubMed ID: 25506704
[TBL] [Abstract][Full Text] [Related]
32. Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs.
de Blois E; Chan HS; de Zanger R; Konijnenberg M; Breeman WA
Appl Radiat Isot; 2014 Feb; 85():28-33. PubMed ID: 24365877
[TBL] [Abstract][Full Text] [Related]
33. [The use of a new analogue DGlu-Octagastrin in scintigraphy of medullary thyroid carcinoma].
Kosowicz J; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
Endokrynol Pol; 2006; 57(4):427-30. PubMed ID: 17006848
[TBL] [Abstract][Full Text] [Related]
34.
Rangger C; Klingler M; Balogh L; Pöstényi Z; Polyak A; Pawlak D; Mikołajczak R; von Guggenberg E
Mol Pharm; 2017 Sep; 14(9):3045-3058. PubMed ID: 28728415
[TBL] [Abstract][Full Text] [Related]
35. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607.
Ocak M; Helbok A; Rangger C; Peitl PK; Nock BA; Morelli G; Eek A; Sosabowski JK; Breeman WA; Reubi JC; Decristoforo C
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1426-35. PubMed ID: 21528387
[TBL] [Abstract][Full Text] [Related]
36. Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the
von Guggenberg E; Uprimny C; Klinger M; Warwitz B; Sviridenko A; Bayerschmidt S; di Santo G; Virgolini IJ
J Nucl Med; 2023 Jun; 64(6):859-862. PubMed ID: 36657979
[TBL] [Abstract][Full Text] [Related]
37. A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
Reilly RM; Scollard DA; Wang J; Mondal H; Chen P; Henderson LA; Bowen BM; Vallis KA
J Nucl Med; 2004 Apr; 45(4):701-8. PubMed ID: 15073268
[TBL] [Abstract][Full Text] [Related]
38. Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate.
Petrik M; Laznickova A; Laznicek M; Zalutsky MR
Anticancer Res; 2007; 27(6B):3941-6. PubMed ID: 18225554
[TBL] [Abstract][Full Text] [Related]
39. Formulation of patient dose of ¹⁷⁷Lu-DOTA-TATE in hospital radiopharmacy in India: preparation using in situ methodology vis-a-vis freeze-dried kit.
Das T; Banerjee S
Cancer Biother Radiopharm; 2014 Sep; 29(7):301-2. PubMed ID: 25203147
[No Abstract] [Full Text] [Related]
40. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin.
Laverman P; Roosenburg S; Gotthardt M; Park J; Oyen WJ; de Jong M; Hellmich MR; Rutjes FP; van Delft FL; Boerman OC
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):386-92. PubMed ID: 17934729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
